New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 22, 2013
14:33 EDTISISIsis Pharmaceuticals provides update on CHMP Opinion on KYNAMRO
Isis Pharmaceuticals announced that following Genzyme's request for re-examination, the Committee for Medicinal Products for Human Use of the European Medicines Agency confirmed its previous position and has maintained a negative opinion regarding the marketing authorization application for KYNAMROTM (mipomersen) as a treatment for patients with Homozygous Familial Hypercholesterolaemia. The FDA approved KYNAMRO in the United States in January for the treatment of patients with Homozygous Familial Hypercholesterolaemia.
News For ISIS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 20, 2015
07:20 EDTISISAmerican Association for Cancer Research to hold annual meeting
Subscribe for More Information
April 10, 2015
19:43 EDTISISIsis Pharmaceuticals management to meet with JPMorgan
Subscribe for More Information
April 8, 2015
16:11 EDTISISRegulus files to sell 3.3M shares for Isis Pharmaceuticals
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use